Ying Hao Huang

6444687, Sep 3, 2002

Dec 14, 2000

09/737141

Andrew W. Stamford - Chatham Township NJ
Craig D. Boyle - Branchburg NJ
Ying Huang - East Brunswick NJ

Schering Corporation - Kenilworth NJ

A61K 314545

514318, 514326, 514333, 514341, 51425214, 51425309, 51425402, 51425405, 544295, 544360, 544367, 544370, 546194, 546210, 546256, 5462741

Compounds of the formula I or a pharmaceutically acceptable salt, solvate or N-oxide thereof, wherein X is CHâ or Nâ; Y is H, halogen, trihaloalkyl, alkyl, alkenyl, cycloalkyl, cycloalkyl, SH, âS-alkyl, or âCN. R is alkyl, âCF , cycloalkyl, heterocycloalkyl, heterocycloalkyl-alkyl, heteroarylalky or adamantyl, or optionally substituted phenyl, phenoxyalkyl, phenylthioalkyl, pyridyl, thienyl, thiazolyl, pyrazinyl, 1,2,5,6-tetrahydropyridine or âwherein R and R are hydrogen, alkyl or together form a cycloalkyl, are disclosed, as well as pharmaceutical compositions and methods of using said compounds in the treatment of eating disorders and diabetes.

6632828, Oct 14, 2003

Jul 23, 2002

10/200966

Andrew W. Stamford - Chatham Township NJ
Craig D. Boyle - Branchburg NJ
Ying Huang - East Brunswick NJ

Schering Corporation - Kenilworth NJ

A61K 314545

514333, 514341, 514326, 514318, 51425214, 51425309, 51425402, 51425405, 546194, 546210, 546256, 5462741, 544295, 544360, 544367, 544370

Compounds of the formula I or a pharmaceutically acceptable salt, solvate or N-oxide thereof, wherein X is CHâ or Nâ; Y is H, halogen, trihaloalkyl, alkyl, alkenyl, cycloalkyl, cycloalkyl, SH, âS-alkyl, or âCN. R is alkyl, âCF , cycloalkyl, heterocycloalkyl, heterocycloalkyl-alkyl, heteroarylalky or adamantyl, or optionally substituted phenyl, phenoxyalkyl, phenylthioalkyl, pyridyl, thienyl, thiazolyl, pyrazinyl, 1,2,5,6-tetrahydropyridine or âwherein R and R are hydrogen, alkyl or together form a cycloalkyl, are disclosed, as well as pharmaceutical compositions and methods of using said compounds in the treatment of eating disorders and diabetes.

6667319, Dec 23, 2003

Jul 24, 2002

10/202239

Andrew W. Stamford - Chatham Township NJ
Ying Huang - East Brunswick NJ
Guoqing Li - Staten Island NY

Schering-Plough Corporation - Kenilworth NJ

A61K 314468

514329, 546224, 548557, 548950, 540605, 514426, 514330, 514212, 514210

The present invention discloses compounds which, are novel receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

6894063, May 17, 2005

Mar 12, 2002

10/096390

William J. Greenlee - Teaneck NJ, US
Ying Huang - East Brunswick NJ, US
Joseph M. Kelly - Parlin NJ, US
Stuart W. McCombie - Caldwell NJ, US
Andrew W. Stamford - Chatham Township NJ, US
Yusheng Wu - New York NY, US

Schering Corporation - Kenilworth NJ

A61K031/445
A61K031/435
A61K031/41
C07D421/00
C07C281/00

514315, 514277, 514359, 51421001, 51421201, 546195, 564 37, 540 1, 540484, 548400

A novel class of compounds such as antagonists of the neuropeptide Y Y5 receptor, methods of making such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more diseases associated with the neuropeptide Y Y5 receptor are disclosed.

7304076, Dec 4, 2007

Oct 24, 2003

10/692559

Andrew W. Stamford - Chatham Township NJ, US
Ying Huang - East Brunswick NJ, US
Li Guoqing - Staten Island NY, US

Schering Corporation - Kenilworth NJ

A61K 31/445
C07D 401/12

514316, 546186

The present invention discloses compounds which, are novel receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

7366706, Apr 29, 2008

Nov 23, 2004

10/994248

Hung-yang (Henry) Chang - Scarsdale NY, US
Ying Huang - Yorktown Heights NY, US
Jim Alain Laredo - Katonah NY, US
Jeaha Yang - Stamford CT, US
Ray Ming Yeh - Katonah NY, US

International Business Machines Corporation - Armonk NY

G06F 17/00
G06N 5/00

706 45, 706 46, 706 47

A method for automating the deployment and lifecycle management of an integration solution by using a deployment solution template to gather deployment information, where the integration solution combines components developed separately or on different platforms. The deployment information gathered includes the computing environment topology into which the integration solution is being deployed, as well as the resource requirements and non-functional requirements of the integration solution and its components. The method provides computer implemented models for analyzing the gathered deployment information, and identifying and optimizing deployment options. Choices for selection among identified and optimized options based on non-functional requirements of the integration solution may be displayed to a user of the deployment method. The deployment template may be customized to modify the information being gathered in view of the analysis provided by the models, and in order to use the template and models in subsequent deployments and for the management of the integration solution.

7503032, Mar 10, 2009

Jun 15, 2001

09/881024

Kumar Bhaskaran - Englewood Cliffs NJ, US
Guillermo Gallego - Ridgewood NJ, US
Ying Huang - Yorktown Heights NY, US
Ying T. Leung - Tarrytown NY, US
Nitin R. Nayak - Ossining NY, US
Sanjay E. Ramaswamy - Naperville IL, US

International Business Machines Corporation - Armonk NY

G06F 9/44

717104, 717105, 705 7, 705 10

A computer implemented system analysis and design method for use in a complex business environment characterized by a set of tightly linked business processes captures in a framework a world view of a business decision and/or a business application software system. A world view is defined by business objectives, constraints, assumptions, data, and underlying model used in business decision and/or the application software system. The framework is used to specify and document each business decision and/or business application software system in the complex environment. A BDML (Business Decision Markup Language) is used to implement the framework for specifying the world view of a business decision and/or a business application software system. A BDML processor comprises a syntax processor that checks the syntax correctness and syntax consistency within an individual and between different documents written in BDML, a logic processor that checks logical consistency between different documents written in BDML, in terms of the business objectives, constraints, assumptions, data, and underlying model among the different documents, and a knowledge-based processor including a knowledge base of business decisions, common choices for their decision support models and commercially available decision support systems, the knowledge-based processor providing suggestions for a set of BDML documents to improve consistency using the knowledge base.

7598250, Oct 6, 2009

Aug 4, 2004

10/911030

Jared N. Cumming - Garwood NJ, US
Ying Huang - East Brunswick NJ, US
Guoqing Li - Belle Mead NJ, US
Ulrich Iserloh - Hoboken NJ, US
Andrew Stamford - Chatham Township NJ, US
Corey Strickland - Martinsville NJ, US
Johannes H. Voigt - Union NJ, US
Yusheng Wu - New York NY, US
Jianping Pan - Monmouth Junction NJ, US
Tao Guo - Dayton NJ, US
Douglas W. Hobbs - Yardley PA, US
Thuy X. H. Le - Monmouth Junction NJ, US
Jeffrey F. Lowrie - Pennington NJ, US

Schering Corporation - Kenilworth NJ

A61K 31/506
A61K 31/496
C07D 403/12
C07D 401/14
C07D 405/14
C07D 409/14
C07D 417/14

51425214, 51425401, 51425405, 544295, 544357, 544363, 544364, 544365, 544368, 544369, 544370, 544371, 544372, 546208, 546221, 5462784, 548204, 5483241, 548518, 548556, 548452, 548512

Disclosed are novel compounds of the formulaAlso disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I. Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.